TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01573858

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CC placebo
Description: CC placebo 50 mg every day for 5 days (day 3-7 of cycle), for a total of 4 cycles. Non-response will be defined after 4 weeks of CC Placebo administration with 3 consecutive weekly negative P4 and hCG levels. Then during the fifth week a higher dose consisting of one more tablet per day (up to 3 tablets per day at third or fourth cycles, if they remain non-responders) will be given 5 days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CC placebo
Description: CC placebo 50 mg every day for 5 days (day 3-7 of cycle), for a total of 4 cycles. Non-response will be defined after 4 weeks of CC Placebo administration with 3 consecutive weekly negative P4 and hCG levels. Then during the fifth week a higher dose consisting of one more tablet per day (up to 3 tablets per day at third or fourth cycles, if they remain non-responders) will be given 5 days.
Study: NCT01678196

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VA-CRAFT
Description: VA-CRAFT is an on-line training program that teaches family members how to communicate and interact with Veterans to promote their engagement in needed mental health services for PTSD or Alcohol Use Disorders. 12 on-line sessions.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Participants will have the opportunity to complete the VA-CRAFT training program after 3 months; otherwise no intervention
Study: NCT01952795

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet and exercise
Description: Total caloric intake aimed at maintaining a diet with\> 50% of the caloric content in the form of carbohydrates, less than 10% in the form of saturated fats and 20% from monounsaturated / polyunsaturated (if applicable, up to 25% fat monounsaturated), less than 300 mg / day of dietary cholesterol and about 1.0 g of protein / kg ideal body weight / day.
Study: NCT00864812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium with fluticasone propionate/salmeterol (FSC)
Description: COPD patients treated with tiotropium with fluticasone propionate/salmeterol (FSC)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tiotropium
Description: COPD patients treated with tiotropium
Study: NCT03319017

Intervention type: PROCEDURE
Intervention: Multiple-trauma patients
Description: The blood samples of the patients who agreed on this research are obtained in order to check their inflammatory response factor, and then their medical records are checked to find their initial ABGA result, lactate, C-reactive protein(CRP) known as initial inflammatory response, and procalcitonin.~A patient's whole blood is collected in the tube with ethylene diaminetetracetic acid (EDTA) treatment. A modified method of Boyum's technique is applied so as to separate polymorphonuclear neutrophils. The separated polymorphonuclear neutrophils is collected so as to check apoptosis. And then, in the separated plasma, interleukin(IL)-6 and tumor necrosis factor(TNF)-α are measured, and its correlation with oxygen saturation will be analyzed.
Study: NCT00880906

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophageal dilation
Description: The esophagus is stretched during the upper endoscopy using Maloney dilators or balloon dilatation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroid and Proton Pump Inhibitor Therapy

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Steroid and Proton Pump Inhibitor Therapy
Study: NCT02355535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC-1
Description: PAC-1 is taken orally on days 1-21 of a 28-day cycle.
Study: NCT04247204

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma intrauterine infusion
Description: For all women, basic transvaginal sonography will be done in the 2nd day of frozen embryo transfer (FET) cycle and they will receive standard hormone replacement therapy (HRT) in the form of estradiol valerate tablets (white tablets of Cyclo-Progynova; Bayer Schering Pharma AG, Germany) at a dose of 4mg for 7 days then 6mg for 6 days. Endometrial assessment will be done on day 15 of FET cycle. Those with endometrial thickness between 8-14 mm will be evaluated for endometrial and sub-endometrial vasculature pattern by 3D power Doppler analysis. Then 1 ml of PRP (prepared from autologous blood) will be infused in the uterine cavity and vaginal progesterone 400 mg twice daily will be prescribed for 3 days. Subsequently, D3 embryos will be transferred. Endometrial, sub-endometrial and uterine arterial vascularity pattern will be re-evaluated on the day of ET. Both estradiol valerate tablets and vaginal progesterone will be continued up to 12th week of gestation in case of pregnancy.
Study: NCT01119950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237 12.5 µg once daily
Description: NVA237 12.5 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237 25.0 µg once daily
Description: NVA237 25.0 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237 12.5 µg twice daily
Description: NVA237 12.5 µg via dry powder inhaler twice daily for 28 days during either period 1 or during period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237 50.0 µg once daily
Description: NVA237 50.0 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237 25.0 µg twice daily
Description: NVA237 25.0 µg via dry powder inhaler twice daily for 28 days during either period 1 or during period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237 100.0 µg once daily
Description: NVA237 100.0 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237 50.0 µg twice daily
Description: NVA237 50.0 µg via dry powder inhaler twice daily for 28 days during either period 1 or during period 2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to NVA237 once daily
Description: Placebo to NVA237 via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
Study: NCT03269019

Intervention type: DIAGNOSTIC_TEST
Intervention: HIT with thrombosis
Description: Testing thrombin-antithrombin complex, d-dimer, fibrin degradation products and Thrombelastograghy.

Intervention type: DIAGNOSTIC_TEST
Intervention: HIT with thrombosis
Description: Testing thrombin-antithrombin complex, d-dimer, fibrin degradation products and Thrombelastograghy.
Study: NCT01377623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine group
Description: Subjects undergoing one or two level spinal fusion surgery will be screened for eligibility to participate in the study. Subject will be screened, recruited and randomized during the preadmission visit or the day of surgery. Eligible subjects will be randomized to one of the two treatment group in1:1 ratio to receive either DEX or matching placebo (PBO, LR).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Fifty six subjects (28 in each arm) will be enrolled. Subjects undergoing one or two level spinal fusion surgery will be screened for eligibility to participate in the study. Subject will be screened, recruited and randomized during the preadmission visit or the day of surgery. Eligible subjects will be randomized to one of the two treatment group in1:1 ratio to receive either DEX or matching placebo (PBO, LR).
Study: NCT02931851

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ICU Families Website
Description: Professionally developed website for relatives of ICU patients

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Standard Information provided online
Study: NCT00434018

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wheelchair Skills Training
Description: Subjects are provided with five weeks of wheelchair skills training, tailored to meet their needs.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Basic Health Education
Description: Five sessions are held with subjects to provide them with educational information regarding health related issues - such as nutrition, proper hand hygiene, sports, etc.
Study: NCT00057850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Study: NCT03895788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: niraparib
Description: Niraparib will be administered as a flat-fixed dose (100mg or 200 mg, daily) depending on the cohort the patient is enrolled to, and not by body weight or body surface area. Each dose should be swallowed whole without chewing. The consumption of water is permissible. Patients should take doses at approximately the same times each day, and record this information in the patient diary. Patients will be provided with a diary in which to record their intake of study drug. However, the actual number of doses taken by the patient must be calculated from the number of tablets dispensed and returned.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivanib
Description: Brivanib will be administered as a flat-fixed dose (200mg, 400 mg, or 600 mg daily) depending on the cohort the patient is enrolled to, and not by body weight or body surface area.
Study: NCT01460342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: 5 mg (2 x 2.5-mg tablets), given once daily as oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets (identical to 2.5-mg tadalafil tablets) given orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 tablets (identical to 2.5-mg tadalafil tablets) given orally once daily.
Study: NCT02866214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Film Coated Tablets of Donifoxate (Eva Pharma company ) 40mg administered thrice weekly post hemodialysis session

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film Coated Tablets (Placebo) to be administered thrice weekly post hemodialysis session.~same color, taste , size . Same all ingredients except Febuxostat (Active ingredient) .
Study: NCT03498716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered by IV, 600 mg/m\^2 every 2 weeks for 4 doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered by IV, 600 mg/m\^2 every 2 weeks for 4 doses
Study: NCT02107014

Intervention type: DRUG
Group type: OTHER
Intervention: Low Dose Naltrexone
Description: Naltrexone 4.5 mg p.o. nocte
Study: NCT02276508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E. coli Nissle 1917
Description: Participants will all take E. coli Nissle 1917 orally administered medication for 30 days
Study: NCT01848548

Intervention type: PROCEDURE
Intervention: Superior Laryngeal Nerve Block using the Thyrohyoid Membrane as an Anatomic Landmark
Description: The needle is introduced just lateral to midline above the thyroid notch in a slightly medial direction so as to enter the thyrohyoid membrane, and inserted about 1-1.5 cm. Three milliliters of 2% lidocaine is injected.
Study: NCT02852863

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gum
Description: Subjects will fast for a minimum of 8 hours. A baseline ultrasound assesment will be performed to evaluate gastric content. Next, subjects will chew sugarless gum for one hour with changes of gum every 20 minutes (a total of 3 gums will be chewed per subject). Once the last gum is chewed, the gum will be disposed in the trashcan. Three more ultrasound assessments will take place: immediately after one hour of chewing gum, and at the first and second hour after chewing gum has stopped. The content will be classified as empty, with fluids, or with solid. In case of fluids, volume will be measured.
Study: NCT01591616

Intervention type: DRUG
Group type: OTHER
Intervention: lidocaine and prilocaine
Description: Appropriate dose of Oraqix based on weight will be given before tooth extraction
Study: NCT03525119

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDV
Description: TDV SC injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDV
Description: TDV SC injection

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: HAV Vaccine
Description: HAV Vaccine IM injection.
Study: NCT04719169

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fluoroscopic enema
Description: Fluoroscopic enema
Study: NCT02934048

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 7-day triple regimen guided by AST
Description: Patients in this group will receive a 7-day triple regimen to eradicate H. pylori. The regimen is consist of a PPI and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 10-day triple regimen guided by AST
Description: Patients in this group will receive a 10-day triple regimen to eradicate H. pylori. The regimen is consist of a PPI and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 14-day triple regimen guided by AST
Description: Patients in this group will receive a 14-day triple regimen to eradicate H. pylori. The regimen is consist of a PPI and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.
Study: NCT03516019

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: personalized notices
Description: The personalized notices take into account if data were received over the previous week, and accordingly encourages the participant to use the device and send her data, or encourages the participant to continue using the device and sending data. A library of personalized notices with alternative motivational content was developed. Each time a notification is sent, it will be drawn at random from the library.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: personalized notices
Description: The personalized notices take into account if data were received over the previous week, and accordingly encourages the participant to use the device and send her data, or encourages the participant to continue using the device and sending data. A library of personalized notices with alternative motivational content was developed. Each time a notification is sent, it will be drawn at random from the library.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: personalized notices
Description: The personalized notices take into account if data were received over the previous week, and accordingly encourages the participant to use the device and send her data, or encourages the participant to continue using the device and sending data. A library of personalized notices with alternative motivational content was developed. Each time a notification is sent, it will be drawn at random from the library.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: personalized notices
Description: The personalized notices take into account if data were received over the previous week, and accordingly encourages the participant to use the device and send her data, or encourages the participant to continue using the device and sending data. A library of personalized notices with alternative motivational content was developed. Each time a notification is sent, it will be drawn at random from the library.
Study: NCT00828412

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EpiCeram Skin Barrier Emulsion
Description: topical cream, twice daily, 6 weeks
Study: NCT03516019

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard notices
Description: The standard notices which are neutral and invite participants to wear the watch daily and to measure their blood pressure weekly.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard notices
Description: The standard notices which are neutral and invite participants to wear the watch daily and to measure their blood pressure weekly.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard notices
Description: The standard notices which are neutral and invite participants to wear the watch daily and to measure their blood pressure weekly.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard notices
Description: The standard notices which are neutral and invite participants to wear the watch daily and to measure their blood pressure weekly.
Study: NCT03525119

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HAV Vaccine
Description: HAV Vaccine IM injection.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: TDV Placebo
Description: Placebo-matching (normal saline (0.9% NaCl) SC injection.
Study: NCT03516019

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: am notices
Description: notifications sent at 7 am.
Study: NCT00828412

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desonide Cream 0.05%
Description: topical cream, twice daily, 6 weeks
Study: NCT03348137

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03516019

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: am notices
Description: notifications sent at 7 am.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: am notices
Description: notifications sent at 7 am.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: am notices
Description: notifications sent at 7 am.
Study: NCT03525119

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HAV Vaccine Placebo
Description: Placebo-matching (normal saline (0.9% NaCl) IM injection.
Study: NCT03516019

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pm notices
Description: notifications sent at 7 pm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pm notices
Description: notifications sent at 7 pm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pm notices
Description: notifications sent at 7 pm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pm notices
Description: notifications sent at 7 pm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: weekday notices
Description: notifications sent on Wednesday

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: weekday notices
Description: notifications sent on Wednesday

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: weekday notices
Description: notifications sent on Wednesday

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: weekday notices
Description: notifications sent on Wednesday
Study: NCT03743090

Intervention type: DIAGNOSTIC_TEST
Intervention: Polysomnography.
Description: A polysomnography will be performed for all of the patients the day before surgery (value of reference), and on the second postoperative day (in order to examine the influence of ECC on the development of OSA).

Intervention type: DIAGNOSTIC_TEST
Intervention: Polysomnography.
Description: A polysomnography will be performed for all of the patients the day before surgery (value of reference), and on the second postoperative day (in order to examine the influence of ECC on the development of OSA).
Study: NCT03361124

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxytocin
Description: Administration of additional 20 mU Oxytocin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Administration of additional 20 mU Oxytocin
Study: NCT04336189

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (SP)
Description: SP (Kamsidar) will be supplied by Kampala Pharmaceutical Industries (KPI), Uganda. SP will be given as a single dose consisting of 3 full strength tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (SP)
Description: SP (Kamsidar) will be supplied by Kampala Pharmaceutical Industries (KPI), Uganda. SP will be given as a single dose consisting of 3 full strength tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin-piperaquine (DP)
Description: DP (Duo-Cotecxin) will be supplied by Holley-Cotec, Beijing, China. DP will consist of 3 full strength tablets given once a day for 3 consecutive days.
Study: NCT03460158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Restylane-L®
Description: Restylane-L® for the indication for mid-to-deep dermal implantation for moderate to severe facial wrinkles and folds, such as nasolabial folds.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Restylane-L® Lyft
Description: Restylane-L® Lyft is for the indication of implantation into the deep dermis to superficial subcutis for the correction of moderate to severe facial folds and wrinkles, such as nasolabial folds and malars (cheek/cheek bone area).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Restylane Silk®
Description: Restylane Silk® is for the indication for submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids in patients over the age of 21.
Study: NCT01065116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL Blister-packs with Instruction leaflets
Description: AL Blister packs with instruction leaflets will be dispensed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AL unit dose age specific pre-packs
Description: Age specific colour coded Unit dose pre-packs will be used
Study: NCT04336189

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin-piperaquine (DP)
Description: DP (Duo-Cotecxin) will be supplied by Holley-Cotec, Beijing, China. DP will consist of 3 full strength tablets given once a day for 3 consecutive days.
Study: NCT02845882

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine
Description: Prednisone 60 mg/m2 per day,d1-28, then taper over 9 days; Vincristine 1.5 mg/m2 per day (max 2 mg),d1,8, 15, 22; Daunorubicin 30 mg/m2 per dose,d5,12,19; Pegylated-asparaginase 2000 IU/m2 per dose,d16,36,57; Cyclophosphamide 1000 mg/m2 per dose, d36, 57; Cytarabine 75 mg/m2 /d, d36-42,d 57-63; 6-Mercaptopurine 60 mg/m2 per day, d36-42, 57-63; Triple it, d8,29,36,57 1,8, 15, 22
Study: NCT02688296

Intervention type: DEVICE
Intervention: Fibulock
Description: Fibulock intramedullary implant will be used to repair fibula fractures

Intervention type: DEVICE
Intervention: Fibulock
Description: Fibulock intramedullary implant will be used to repair fibula fractures

Intervention type: DEVICE
Intervention: Fibulock
Description: Fibulock intramedullary implant will be used to repair fibula fractures